Cannabics Pharmaceuticals Inc (OTCMKTS:CNBX) has completed the pre-clinical development of innovative formulation that comprise cannabidiol to treat colon cancer. The innovative formulation has shown significant anti-tumor properties in the trial conducted at Israel based Cannabics Pharmaceuticals HTS facility.
Evaluates efficacy and safety of innovative formulation
Cannabics Pharmaceuticals expects to evaluate the efficacy and safety of the innovative formulation that comprise higher levels of CBGA and CBDV. Both CBGA and CBDV have shown complex combinatorial anti-tumor properties. These cannabinoids have not demonstrated any side effects. Therefore, both the cannabinoids are ideal for treating the patients without intoxication.
The R&D team at Israel based facility has studied combinatorial effects of the purified cannabinoids. They have also divulged complex revelations among CBD compounds. Some of the cannabinoids have demonstrated antagonistic effects on gastrointestinal cancer cells viability.
According to various studies conducted on different disease models and in clinical studies, natural CBD extracts have demonstrated entourage effects. Overall, the purified cannabinoids are less effective and more toxic.
The R&D team is striving to develop innovative proprietary formulations using its HTS platform to screen the necrotic effects of combinations of the purified cannabinoids. It has screened the purified cannabinoids and their combinations for anti-tumor effects.
Recruits Prof. Zamir Halpern
Cannabics Pharmaceuticals has recruited Prof. Zamir Halpern to the scientific board of advisors. He is currently working as a senior physician at a Tel-Aviv, Israel based Gastroenterology institute. Post joining the company, he will involve in evaluating the novel formulation to treat colon cancer. During a trial held at Cannabics Pharmaceuticals HTS facility, the innovative formulation has demonstrated positive differential necrotic effects of CBD on colon cancer cells.
In his previous stint, Halpern held the positions of Chairman at Israeli Gastroenterology Association, Israeli Association of the Study of Liver, and National Council for Food. He is also serving as a Chairman at the National Gastro Nutrition and Liver Diseases Council.
The US public company – Cannabics Pharmaceuticals is engaged in developing a platform, which uses innovative drug screening tools for creating CBD based therapies to treat cancer. The tools helps to assess the effectiveness of the formulation based on patients profile.